

Naga Chalasani

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9135667/naga-chalasani-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

120 papers	12,731 citations	35 h-index	112 g-index
137 ext. papers	16,846 ext. citations	7.1 avg, IF	6.44 L-index

#	Paper	IF	Citations
120	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2018 , 67, 328-357	11.2	2641
119	Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. <i>New England Journal of Medicine</i> , 2010 , 362, 1675-85	59.2	2119
118	Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2015 , 385, 956-65	40	1421
117	Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 1659-68	27.4	721
116	ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>American Journal of Gastroenterology</i> , 2014 , 109, 950-66; quiz 967	0.7	469
115	Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. <i>Gastroenterology</i> , 2015 , 148, 1340-52.e7	13.3	466
114	Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010 , 52, 913-24	11.2	309
113	Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. <i>Drug Safety</i> , 2009 , 32, 55-68	5.1	308
112	Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. <i>Gastroenterology</i> , 2018 , 155, 443-457.e17	13.3	308
111	Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. <i>Hepatology</i> , 2014 , 59, 661-70	11.2	249
110	Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. <i>Journal of Hepatology</i> , 2018 , 68, 305-315	13.4	241
109	Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia. <i>Gastroenterology</i> , 2016 , 150, 785-90	13.3	223
108	Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. <i>Hepatology</i> , 2014 , 60, 679-86	11.2	152
107	Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 156-163.e2	6.9	149
106	Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. <i>Gastroenterology</i> , 2014 , 147, 96-108.e4	13.3	142
105	Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2008 , 48, 829-34	13.4	141
104	Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 948-963	15.1	135

103	Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2018 , 67, 134-144	11.2	124
102	Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. <i>Contemporary Clinical Trials</i> , 2009 , 30, 88-96	2.3	118
101	Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. <i>Hepatology</i> , 2019 , 69, 760-773	11.2	114
100	Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 103-112.e2	6.9	100
99	The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis. <i>Hepatology</i> , 2018 , 67, 1284-1302	11.2	74
98	Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. <i>American Journal of Gastroenterology</i> , 2015 , 110, 1450-9	0.7	71
97	Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis. <i>Hepatology</i> , 2020 , 71, 495-509	11.2	71
96	Nonalcoholic Fatty Liver Disease in Latinos. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 5-12; quiz e9-10	6.9	61
95	Death and liver transplantation within 2 years of onset of drug-induced liver injury. <i>Hepatology</i> , 2017 , 66, 1275-1285	11.2	58
94	Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. <i>Clinical and Experimental Immunology</i> , 2015 , 180, 40-51	6.2	56
93	Serum proteomic profiling in patients with drug-induced liver injury. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 600-12	6.1	51
92	Fatty acid desaturase 1 gene polymorphisms control human hepatic lipid composition. <i>Hepatology</i> , 2015 , 61, 119-28	11.2	47
91	Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 809-821	6.1	47
90	Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH. <i>Hepatology</i> , 2020 , 72, 1219-1229	11.2	39
89	Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2019 , 156, 88-95.e5	13.3	39
88	Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance. <i>Liver International</i> , 2017 , 37, 757-764	7.9	35
87	Saroglitazar, a PPAR- γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. <i>Hepatology</i> , 2021 , 74, 1809-1824	11.2	35
86	Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1676-82.e1	6.9	34

85	Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). <i>Liver International</i> , 2015 , 35, 1623-32	7.9	34
84	Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. <i>American Journal of Gastroenterology</i> , 2019 , 114, 1626-1635	0.7	34
83	Effects of Age, Sex, Body Weight, and Quantity of Alcohol Consumption on Occurrence and Severity of Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1831-1838.e3	6.9	33
82	Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. <i>New England Journal of Medicine</i> , 2021 , 385, 1559-1569	59.2	33
81	Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 332-344	6.1	32
80	Increasing Economic Burden in Hospitalized Patients With Cirrhosis: Analysis of a National Database. <i>Clinical and Translational Gastroenterology</i> , 2019 , 10, e00062	4.2	32
79	ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. <i>American Journal of Gastroenterology</i> , 2021 , 116, 878-898	0.7	31
78	Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. <i>Liver International</i> , 2019 , 39, 924-932	7.9	31
77	NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 301-9	6.1	30
76	Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 317-328	6.1	29
75	Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis. <i>Hepatology</i> , 2021 , 73, 571-585	11.2	29
74	Fecal Microbiome Distinguishes Alcohol Consumption From Alcoholic Hepatitis But Does Not Discriminate Disease Severity. <i>Hepatology</i> , 2020 , 72, 271-286	11.2	28
73	Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2015 , 60, 360-7	2.8	28
72	Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1195-1204	6.1	23
71	Heavy Consumption of Alcohol is Not Associated With Worse Outcomes in Patients With Idiosyncratic Drug-induced Liver Injury Compared to Non-Drinkers. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 722-729.e2	6.9	22
70	Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1639-1651	6.1	22
69	A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2597-2605.e4	6.9	22
68	Lipopolysaccharide downregulates macrophage-derived IL-22 to modulate alcohol-induced hepatocyte cell death. <i>American Journal of Physiology - Cell Physiology</i> , 2017 , 313, C305-C313	5.4	20

67	Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2018 , 22, 189-199	4.6	19
66	Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury. <i>Hepatology</i> , 2021 , 73, 268-281	11.2	19
65	Drug Hepatotoxicity: Environmental Factors. <i>Clinics in Liver Disease</i> , 2017 , 21, 103-113	4.6	18
64	Leveraging Social Networking Sites for an Autoimmune Hepatitis Genetic Repository: Pilot Study to Evaluate Feasibility. <i>Journal of Medical Internet Research</i> , 2018 , 20, e14	7.6	16
63	Gender Matters: Characteristics of Hepatocellular Carcinoma in Women From a Large, Multicenter Study in the United States. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1486-1495	0.7	16
62	Development and Validation of a Model Consisting of Comorbidity Burden to Calculate Risk of Death Within 6 Months for Patients With Suspected Drug-Induced Liver Injury. <i>Gastroenterology</i> , 2019 , 157, 1245-1252.e3	13.3	15
61	Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1205-1213	6.1	14
60	Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis. <i>Hepatology International</i> , 2018 , 12, 97-106	8.8	14
59	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. <i>Journal of Autoimmunity</i> , 2020 , 114, 102514	15.5	14
58	Acute Alcoholic Hepatitis: Natural History and Predictors of Mortality Using a Multicenter Prospective Study. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2017 , 1, 37-48	3.1	13
57	Randomized Controlled Trial of a Leucine-Metformin-Sildenafil Combination (NS-0200) on Weight and Metabolic Parameters. <i>Obesity</i> , 2019 , 27, 59-67	8	13
56	Perilipin Staining Distinguishes Between Steatosis and Nonalcoholic Steatohepatitis in Adults and Children. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 145-147	6.9	12
55	Obesity associated molecular forms of C-reactive protein in human. <i>PLoS ONE</i> , 2014 , 9, e109238	3.7	12
54	Effects of Rare Microbiome Taxa Filtering on Statistical Analysis. <i>Frontiers in Microbiology</i> , 2020 , 11, 607325	3.7	12
53	Interaction between the patatin-like phospholipase domain-containing protein 3 genotype and coffee drinking and the risk for acute alcoholic hepatitis. <i>Hepatology Communications</i> , 2018 , 2, 29-34	6	11
52	Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. <i>Drug Safety</i> , 2019 , 42, 701-711	5.1	11
51	Early predictors of outcomes of hospitalization for cirrhosis and assessment of the impact of race and ethnicity at safety-net hospitals. <i>PLoS ONE</i> , 2019 , 14, e0211811	3.7	10
50	Changing epidemiology and outcomes of acute kidney injury in hospitalized patients with cirrhosis - a US population-based study. <i>Journal of Hepatology</i> , 2020 , 73, 1092-1099	13.4	10

49	Risk factors for hepatocellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study. <i>World Journal of Hepatology</i> , 2017 , 9, 385-390	3.4	10
48	Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	10
47	Palliative Care and Hospice Referrals in Patients with Decompensated Cirrhosis: What Factors Are Important?. <i>Journal of Palliative Medicine</i> , 2020 , 23, 1066-1075	2.2	9
46	An exploratory genome-wide analysis of genetic risk for alcoholic hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2017 , 52, 1263-1269	2.4	9
45	Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis. <i>Journal of Clinical Gastroenterology</i> , 2019 , 53, 750-758	3	9
44	Challenges in Patient Enrollment and Retention in Clinical Studies for Alcoholic Hepatitis: Experience of the TREAT Consortium. <i>Alcoholism: Clinical and Experimental Research</i> , 2017 , 41, 2000-2006	2.7	7
43	Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans. <i>Aging</i> , 2016 , 9, 26-40	5.6	7
42	ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. <i>Hepatology</i> , 2021 , 73, 2238-2250	11.2	7
41	Genetic Variants Associated With Obesity and Insulin Resistance in Hispanic Boys With Nonalcoholic Fatty Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018 , 66, 789-796	2.8	6
40	In a pilot study, reduced fatty acid desaturase 1 function was associated with nonalcoholic fatty liver disease and response to treatment in children. <i>Pediatric Research</i> , 2018 , 84, 696-703	3.2	6
39	Extrahepatic Autoimmune Diseases are Prevalent in Autoimmune Hepatitis Patients and Their First-Degree Relatives: Survey Study. <i>Interactive Journal of Medical Research</i> , 2018 , 7, e18	2.1	6
38	Exploratory Study of Autoantibody Profiling in Drug-Induced Liver Injury with an Autoimmune Phenotype. <i>Hepatology Communications</i> , 2020 , 4, 1651-1663	6	6
37	Association of State Medicaid Expansion With Racial/Ethnic Disparities in Liver Transplant Wait-listing in the United States. <i>JAMA Network Open</i> , 2020 , 3, e2019869	10.4	5
36	Admission plasma uromodulin and the risk of acute kidney injury in hospitalized patients with cirrhosis: a pilot study. <i>American Journal of Physiology - Renal Physiology</i> , 2019 , 317, G447-G452	5.1	5
35	Fatty Acid Desaturase 1 Influences Hepatic Lipid Homeostasis by Modulating the PPAR- α /FGF21 Axis. <i>Hepatology Communications</i> , 2021 , 5, 461-477	6	5
34	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. <i>Journal of Hepatology</i> , 2021 ,	13.4	4
33	ADH1B*2 Is Associated With Reduced Severity of Nonalcoholic Fatty Liver Disease in Adults, Independent of Alcohol Consumption. <i>Gastroenterology</i> , 2020 , 159, 929-943	13.3	4
32	Safety and Efficacy of Bariatric Surgery in Cirrhosis Patients With Extreme Obesity. <i>Annals of Surgery</i> , 2020 , 275,	7.8	4

31	Novel HLA Class I Alleles Outside the Extended DR3 Haplotype Are Protective against Autoimmune Hepatitis. <i>Clinical and Translational Gastroenterology</i> , 2019 , 10, e00032	4.2	4
30	Development and Validation of a Model to Predict Acute Kidney Injury in Hospitalized Patients With Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2019 , 10, e00075	4.2	4
29	Algorithm for blood-based panel of methylated DNA and protein markers to detect early-stage hepatocellular carcinoma with high specificity.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4577-4577	2.2	3
28	Associations Between Mean Arterial Pressure and Poor ICU Outcomes in Critically Ill Patients With Cirrhosis: Is 65 The Sweet Spot?. <i>Critical Care Medicine</i> , 2020 , 48, e753-e760	1.4	3
27	Hospital-Acquired Versus Community-Acquired Acute Kidney Injury in Patients With Cirrhosis: A Prospective Study. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1505-1512	0.7	3
26	Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial. <i>Hepatology Communications</i> , 2021 , 5, 786-797	6	3
25	Distinctive Features and Outcomes of Hepatocellular Carcinoma in Patients With Alcohol-Related Liver Disease: A US Multicenter Study. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00139	4.2	2
24	Persistent Hyperactivation of Endothelial Cells in Patients with Alcoholic Hepatitis. <i>Alcoholism: Clinical and Experimental Research</i> , 2020 , 44, 1075-1087	3.7	2
23	Reply. <i>Hepatology</i> , 2018 , 67, 2478-2479	11.2	2
22	High quality diet, physical activity and college education are associated with low risk of NAFLD among the U.S. population. <i>Hepatology</i> , 2021 ,	11.2	2
21	Transcriptomic Analysis Reveals the MicroRNAs Responsible for Liver Regeneration Associated With Mortality in Alcohol-Associated Hepatitis. <i>Hepatology</i> , 2021 , 74, 2436-2451	11.2	2
20	Significant Medical Comorbidities Are Associated With Lower Causality Scores in Patients Presenting With Suspected Drug-Induced Liver Injury. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00141	4.2	2
19	Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin. <i>Journal of Pediatrics</i> , 2021 , 239, 161-167.e5	3.6	2
18	Getting New Drugs Approved in Portal Hypertension: Problems and Proposals. <i>Current Hepatology Reports</i> , 2016 , 15, 187-189	1	1
17	Clinical Characteristics and Outcomes of Mild to Moderate Alcoholic Hepatitis. <i>GastroHep</i> , 2019 , 1, 161-165		1
16	Differential Expression of miRNAs in Nontumor Liver Tissue of Patients With Hepatocellular Cancer Caused by Nonalcoholic Steatohepatitis Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 465-467	6.9	1
15	Practice patterns and outcomes associated with intravenous albumin in patients with cirrhosis and acute kidney injury. <i>Liver International</i> , 2021 ,	7.9	1
14	Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis. <i>Hepatology</i> , 2021 ,	11.2	1

13	Role of candidate gene variants in modulating the risk and severity of alcoholic hepatitis. <i>Alcoholism: Clinical and Experimental Research</i> , 2021 , 45, 709-719	3.7	1
12	Contemporary Trends in Hospitalizations for Comorbid Chronic Liver Disease and Substance Use Disorders. <i>Clinical and Translational Gastroenterology</i> , 2021 , 12, e00372	4.2	1
11	MELD-Na Is More Strongly Associated with Risk of Infection and Outcomes Than Other Characteristics of Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 247-256	4	1
10	The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD. <i>Clinical and Translational Gastroenterology</i> , 2021 , 12, e00400	4.2	1
9	Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2021 ,	13.4	1
8	Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis 2018 , 68, 349		1
7	Prevalence of High-risk Nonalcoholic Steatohepatitis (NASH) in the United States: Results From NHANES 2017-2018.. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	1
6	Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents. <i>Clinical and Translational Gastroenterology</i> , 2021 , 12, e00420	4.2	0
5	Hepatocellular Carcinoma in Hispanic Patients: Trends and Outcomes in a Large United States Cohort. <i>Hepatology Communications</i> , 2020 , 4, 1708-1716	6	0
4	Response to Levy. <i>American Journal of Gastroenterology</i> , 2015 , 110, 471-2	0.7	
3	In Memoriam-Lawrence Lumeng, MD: Researcher, Clinician, Leader, Mentor, Family Man, and Friend. <i>Gastroenterology</i> , 2017 , 153, 873-874	13.3	
2	Irreversible inhibition of intestinal cytochrome 3A (CYP3A) by clarithromycin. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, P61-P61	6.1	
1	Comorbidity Burden May Be Associated with Increased Mortality in Patients with Severe Acute Liver Injury Referred for Liver Transplantation. <i>Annals of Transplantation</i> , 2020 , 25, e926453	1.4	